Published • loading... • Updated
Scenic joins MJFF program to test Parkinson’s therapy approach
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Scenic joins MJFF program to test Parkinson’s therapy approach
Scenic Biotech has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program to study its PLA2G15 inhibitors as a potential treatment approach for Parkinson’s disease, including in people with LRRK2 gene mutations. The program is an initiative from The Michael J. Fox Foundation (MJFF) designed to identify biomarkers and accelerate the development of new disease-modifying therapies targeting LRRK2 biology. Mutations in LRRK2 are among t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
